Related Experiment Video

Updated: Jan 12, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.5K

Oncogenic KRAS mutations drive immune suppression through immune-related regulatory network and metabolic

Lin Tian1,2, Hui Li1,2,3, Heran Cui3

  • 1Medical Oncology Translational Research Lab, Jilin Cancer Hospital, Changchun, China.

Cell Death & Disease
|November 3, 2025
PubMed

Insights

The KRAS mutation drives cancer growth by altering immune signaling and metabolism. Understanding these KRAS-driven changes in the tumor microenvironment is key for developing new cancer immunotherapies.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Biology

Background:

  • KRAS mutations are the most common oncogenic alterations in human cancers.
  • KRAS activation drives tumor development and growth via downstream signaling pathways.
  • KRAS influences the tumor immune microenvironment and host immune responses.

Purpose of the Study:

  • To review the features of the immune microenvironment associated with KRAS mutations.
  • To discuss how KRAS remodels the tumor immune microenvironment.
  • To provide insights for developing effective immunotherapies for KRAS-mutant tumors.

Main Methods:

  • Literature review of studies on KRAS mutations and the tumor immune microenvironment.
  • Analysis of KRAS-mediated regulation of immune-related molecules and inflammatory factors.
  • Examination of KRAS-triggered metabolic pathways influencing immune cells.

Main Results:

  • KRAS mutations significantly modulate immune-related signaling and inflammatory pathways.
  • KRAS influences immune cell phenotype and function through tumor metabolic reprogramming.
  • KRAS remodeling of the immune microenvironment involves various immune molecules, inflammatory factors, and metabolic pathways.

Conclusions:

  • KRAS mutations extensively shape the tumor immune microenvironment.
  • Targeting KRAS-associated immune and metabolic alterations may enhance immunotherapy efficacy.
  • Further research into KRAS-driven immune modulation is crucial for advancing cancer treatment.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

615
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.6K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.1K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.3K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
5.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.0K